---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-042857"
form_type: "8-K"
ticker: "FEED"
cik: "0001326706"
company_name: "ENvue Medical, Inc."
filed_at: "2023-11-28T23:59:59+00:00"
generated_at: "2026-06-07T20:50:10.882374+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NanoVibronix signs research agreement with University of Michigan for RCT of UroShield

## Summary
- UroShield study targets nursing home residents; aims to reduce UTIs, catheter blockages, and pain.
- Pilot of 20 patients precedes full study of over 300 patients; expected to start H1 2024.
- Positive results could support application to FDA for permanent clearance; currently under Enforcement Discretion.
- Study led by Center for Research and Innovations in Special Populations (CRIISP) at University of Michigan.

## SEC filing metadata
- accession: 0001493152-23-042857
- form_type: 8-K
- ticker: FEED
- cik: 0001326706
- company_name: ENvue Medical, Inc.
- filed_at: 2023-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326706/000149315223042857/0001493152-23-042857-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326706/000149315223042857/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-042857
- JSON: https://secwatch.observer/filing/0001493152-23-042857.json
- Plain text: https://secwatch.observer/filing/0001493152-23-042857.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.